AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06745869 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diaphragmatic breathing exercise training
Description: At the end of the training, participants will be asked to do an exercise session and this session will be observed. Training will continue until participants learn and apply the exercise correctly.~5-minute warm-up and cool-down periods will be applied at the beginning and end of each exercise session. Exercises will be done twice a day, morning and evening, for 8 weeks.~In order to follow the exercise, participants will be given diaphragmatic breathing exercise tracking cards with date and session information. In addition, participants will be followed up weekly on one of the rehearsal days to ensure their adaptation to the exercise.
Study NCT06745869 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Description: The intensity of the aerobic exercise program will be calculated for each participant using the Karvonen formula. Accordingly, each participant will be given a brisk walking program on a suitable surface, which will be created specifically for the individual to reach the target heart rate range within the scope of the aerobic exercise program; they will apply a 45-minute session, 3 days a week, for 8 weeks.
Study NCT06745674 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: a mobile app-delivered Acceptance Commitment Therapy (ACT)
Description: The study utilized a specially tailored internet-based self-help ACT program for cancer patients. It consisted of an introductory module and six core intervention modules: (1) Refusing Avoidance; (2) Accepting Distress; (3) Living in the Present Moment; (4) Observing Yourself Psychologically; (5) Exploring Meaningful Values; and (6) Committing to Action. Each module, designed to take 30-60 minutes, was delivered over a two-week period.
Study NCT06744998 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemopatch® (Baxter)
Description: HEMOPATCH® is an absorbable collagen pad intended for sealing and hemostasis
Study NCT06745154 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo nasal swab collection
Study NCT06745154 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cognitive Assessment
Description: Undergo cognitive assessment
Study NCT06745154 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Ancillary studies
Study NCT06745154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement
Description: Given nicotine patches, gum, or lozenges
Study NCT06745154 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Intervention
Description: Receive access to the Ohio Tobacco Quit Line
Study NCT06745154 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT06745154 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco Cessation Counseling
Description: Participate in counseling sessions
Study NCT05051059 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Health related quality of life (HRQoL) assessment
Description: Quality of Life Questionnaire C-30 (QLQ-C30), Impact on Participation and Autonomy Questionnaire (IPAQ) and Musculoskeletal Tumor Society Score (MSTS)
Study NCT06546670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITU512
Description: ITU512 is an investigational, oral, low molecular weight (LMW) compound.
Study NCT06546670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: An inactive substance that looks like and is given the same way as ITU512. The effect(s) of ITU512 will be evaluated against the placebo. Placebos are designed as a control and to have no real effect.
Study NCT06073132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-203
Description: The investigational product is formulated as 1% topical ointment
Study NCT06073132 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle-only control study medication is the same formulation as investigational product without active ingredient
Study NCT05198583 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-Fit
Description: The intervention lasts a total of 8 weeks and is structured in 3 modules. The first module consists of a weekly strategy training in which problems resulting from executive dysfunction are addressed. Online games form the second module. These are games implemented online to promote EF through play. The third module is also based on games: The families receive several board games to play together at home. This third module is voluntary.
Study NCT05154825 — intervention group
Intervention type: OTHER
Intervention: Imaging-Observational
Description: Preoperative standing and supine, intraoperative pre- and post-correction, and postoperative standing imaging as well as imaging collected during follow-up exams for a year following surgery
Study NCT05625503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Verapamil
Description: All patients routinely receive intra-arterial calcium channel blockers during transradial access for coronary angiography.
Study NCT05625503 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nicardipine
Description: Calcium channel blocker
Study NCT05882643 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: moderate to deep neuromuscular blockade
Description: * Maintaining moderate to deep neuromuscular blockade during an intraoperative period (Train-of-four 0-3 count, post-tetanic count > 1)~* Rocuronium (intravenous, 1.0 mg/kg at induction period)
Study NCT05882643 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: shallow to minimal neuromuscular blockade
Description: * Maintaining shallow to minimal neuromuscular blockade during an intraoperative period (Train-of-four 4, post-tetanic count \< 0.9)~* Rocuronium (intravenous, 0.3 mg/kg at induction period)
Study NCT05298878 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Group: Virtual home-based rehabilitation plus usual outpatient care
Description: 14 supervised exercise virtual sessions with Kinesiologist and 10 independent exercise sessions. Each session lasts 40 minutes. The exercises consist of aerobic training; functional lower and upper body strengthening; balance; and flexibility exercises. During the first 10 minutes of the first session of each week, there is an educational session.~Week 1-2: three supervised virtual sessions Week 3-4: two supervised virtual sessions and one independent session. Week 5-8: one supervised virtual session and two independent sessions.
Study NCT06207162 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: fMRI
Description: Participants will be performing tasks while undergoing fMRI. Tasks include Stroop task, Emotion-regulation task and an Ambiguity reward task. There will also be a Resting state: Participants are not presented with any specific stimulus.
Study NCT05438576 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence enabled electrocardiogram (AI-ECG)
Description: An artificial intelligence algorithm which analyses ECG data and generates prediction probabilities for a diagnosis of cardiomyopathy.
Study NCT06443593 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Tablet VitaBliss vitamin B12 (2.2 mcg)
Description: Oral vitamin B12 supplement 2.2 mcg from BLISS WELNESS, Bliss Lifesciences, LLP to be administered once daily for 24 weeks
Study NCT06443593 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Tablet VitaBliss vitamin B12 (2.2 mcg) and Syrup Orofer (5 ml = 50 mg)
Description: Oral vitamin B12 supplement 2.2 mcg from BLISS WELNESS, Bliss Lifesciences, LLP to be administered once daily for 24 weeks and oral iron 25 mg from Emcure Pharmaceuticals Ltd. to be administered once daily for 24 weeks
Study NCT06443593 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Tablet VitaBliss vitamin B12 (2.2 mcg) and Tablet Tayo (60000 IU)
Description: Oral vitamin B12 supplement 2.2 mcg from BLISS WELNESS, Bliss Lifesciences, LLP to be administered once daily for 24 weeks and oral vitamin D3 (60000 IU) from Eris Lifesciences Ltd to be administered once in 3 months for 24 weeks
Study NCT06377592 — intervention group
Intervention type: OTHER
Intervention: Sample collection without intervention
Description: No Intervention
Study NCT06020937 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: TDI
Description: Sniffin' Sticks Threshold and Identification Test
Study NCT06020937 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Trigeminal Test
Description: Test the trigeminal smell answer by a device that releases air and a substance that stimulates the trigeminal response
Study NCT06020937 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cognitive Evaluation by Montreal Cognitive Assessment
Description: Montreal Cognitive assessment
Study NCT06020937 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Anxiety and Depression questionnaire
Description: Specific test to evaluate patient's mood
Study NCT06020937 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Visual Analogue Scale Ratings
Description: * Smell ability (How is your sense of smell right now? 0 cannot smell, 1-3 severe impairment, 4-6 moderate impairment, 7-9 mild impairment, 10 normal)~* Nasal breathing (How well can you breathe through your nose right now? 0 complete nasal obstruction, 1-3 severe impairment, 4-6 moderate impairment, 7-9 mild impairment, 10 normal)
Study NCT05921318 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Beijing protocol
Description: For patients \<55 years and HCT-CI≤ 3：Ara-C(4g/m2/day,-9 days),Bu(9.6mg/kg,-8 days to -6 days),Cy(1,800mg/m2/day,-5 days to -4 days),semustine(250mg/m2,-3 days),ATG(7.5-10 mg/kg,-5 to -2 days)~For patients ≥ 55 years or HCI-CI>3：Ara-C(2g/m2/day,-10 days to -9 days),Bu(9.6mg/kg,-8 days to -6 days),Flu(30mg/m2/day,-6 days to -2 days),Cy(1,000mg/m2/day,-5 days to -4 days),semustine(250mg/m2,-3 days),ATG(7.5-10 mg/kg,-5 to -2 days).
Study NCT06020937 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Quality of smell Questionnaire
Description: Patients will answer to a validated questionnaire
Study NCT04741997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib Pill
Description: Encorafenib 450 mg will be administered orally once per day in continuous 28-day cycles
Study NCT04741997 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Encorafenib Pill
Description: Encorafenib 450 mg will be administered orally once per day in continuous 28-day cycles
Study NCT04741997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib Pill
Description: Binimetinib 45 mg will be administered orally twice per day in continuous 28-day cycles
Study NCT04741997 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Binimetinib Pill
Description: Binimetinib 45 mg will be administered orally twice per day in continuous 28-day cycles
Study NCT04741997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered at a dose of 480 mg IV infusion over 30 minutes every 4 weeks.
Study NCT06382805 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy program
Description: The physiotherapy program will consist of cold-pack, US, transcutaneous electrical stimulation (TENS) and home exercise program. Cold-pack will be applied for 15 minutes. Continuous ultrasound will be applied on lateral epicondylitis with a 5-cm ultrasound head at a dose of 1.5W/cm2 for 5 minutes and a frequency of 1-MHZ. TENS application will be performed with the BTL 4000 combination device. TENS will be applied for 20 minutes, increasing the intensity of the current until the patient feels it. The treatment program will last for a total of two weeks, 5 days a week.
Study NCT06501339 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: maintenance ECT
Description: Frequency of weekly sessions for 1 month, then fortnightly for 5 months
Study NCT06501339 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole tablet
Description: Aripiprazole 10 mg in the morning throughout the study period
Study NCT05560880 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Gait training
Description: Subjects will walk as fast as they can for 30 seconds, followed by a 60 second seated recovery. They will be guarded by a physical therapist at all times.
Study NCT06382805 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio Tape
Description: The longitudinal muscle technique will be applied from the origin to the insertion of the forearm extensor muscles by a researcher with a Kinesio tape application certificate. In addition, transverse kinesio tape will be applied on the elbow using the fascia correction technique. The treatment program will last for a total of two weeks, 5 days a week.
Study NCT05560880 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate Intensity Interval gait training
Description: subjects will walk for 20 minutes at theri best comfortable pace
Study NCT06347978 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: Subjects will be randomized to either ON-OFF (Stimulation-Sham) or OFF-ON (Sham-Stimulation) arms. Patients in the ON-OFF arm will first be treated for up to 12 weeks with the parameters identified during the DBS optimization phase until the washout period. Patients in the OFF-ON will have their devices turned off and will not have their device switched on (activated) until the crossover point.~After completion of the first phase of the trial, patients will undergo another washout phase until they are within 20% of their pre-treatment Y-BOCS II score or 4 weeks have passed, whichever comes first. The purpose of the washout is to eliminate any residual effect of stimulation in the ON group.~Patients will then be advanced to the crossover phase. The participants who were initially randomized to the ON-OFF arm will be moved onto the sham (OFF) period, and the participants who were initially randomized to the OFF-ON group will be moved onto stimulation (ON) period for up to 12 weeks.
Study NCT06382805 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Intensity Laser therapy
Description: High intensity laser applications will be performed using the BTL-6000 (BTL Company, UK) device. The first 5 sessions will be applied to the painful area for 75 seconds at a dose of 4W 6 J/cm2 (analgesic effect) by making circular movements from the center to the outside. The remaining 5 sessions will be applied to the painful area with linear movements for 12 minutes and 30 seconds at a dose of 6W 100-150 J/cm2 (biostimulation effect). The treatment program will last for a total of two weeks, 5 days a week.
Study NCT05683392 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: t:slim X2 insulin pump with Control-IQ technology 2.0
Description: t:slim X2 insulin pump with Control-IQ technology 2.0, and wearing the Dexcom G6 sensor.
Study NCT05783349 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Unique blod sample
Description: sampling of 4mL of blood on lithium heparin tube, the day of frozen embryo implantation
Study NCT05428007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Injectable solutions of sarilumab are formulated in 2 mL of aqueous solution in a 5 mL vial containing 175 mg/ml of sarilumab arginine (8.94 mg), histidine (3.71 mg), polysorbate 20 (2.28 mg), sucrose (57 mg) and Water for Injection USP.Patients will be administered sarilumab at a dose of 150 mg subcutaneously in combination with ipilimumab, nivolumab and relatlimab given intravenously, with nivolumab/relatlimab given intravenously, or sarilumab at a dose of 150 mg subcutaneously given alone.
Study NCT05428007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab Injection
Description: Ipilimumab injection is a sterile, nonpyrogenic, clear to slightly opalescent, colorless to pale yellow solution, single-use, preservative-free, isotonic aqueous solution that may contain particles. It is formulated at a concentration of 5 mg/mL ipilimumab in TRIS hydrochloride (also known as 2-amino-2-hydroxymethyl-1,3-propanediol hydrochloride), sodium chloride, mannitol, pentetic acid (also known as diethylenetriaminepentaacetic acid or DTPA), polysorbate 80, and water at pH 7.0. Sodium hydroxide and/or hydrochloric acid may be used to adjust the pH of the solution. Ipilimumab Injection 200 mg/40 mL (5 mg/mL) is packaged in a 50-cc Type I flint molded glass vials.
Study NCT05428007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab/Relatlimab
Description: The FDC drug product, referred to as nivolumab/relatlimab, contains relatlimab and nivolumab in a single vial in a kit of 2 vials. The product is a sterile, non-pyrogenic, single-use, isotonic aqueous solution for IV infusion. It is formulated at a total protein concentration of 16 mg/mL (4 mg/mL relatlimab and 12 mg/mL nivolumab) and is packaged in a 20-cc glass vial in a kit of two vials. Each vial contains 80 mg of relatlimab and 240 mg of nivolumab.
Study NCT05323734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganaxalone
Description: GNX will be administered
Study NCT05323734 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered
Study NCT05069740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salsalate Pill
Description: Salsalate acts as an NFkB inhibitor to reduce systemic inflammation
Study NCT05069740 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for the salsalate intervention
Study NCT05024214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib + Envafolimab
Description: Lenvatinib will be administered with water orally once a day (with or without food) continuously in 28-day treatment cycle.~Envafolimab, 400 mg per dose, subcutaneous injection, dosed on D1 and then D15 of Treatment Cycle 1, and D1 of Treatment Cycle 2 and every subsequent cycles, with every 28 days as one treatment cycle.
Study NCT05024214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib will be administered with water orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2) in 42-day treatment cycle.
Study NCT05289908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed (1)
Description: Pemetrexed (Alimta, Eli Lilly and Company) is administrated by intrathecal injection, plus dexamethasone, twice per week for 2 weeks, followed by once per week for 4 weeks. The initial dose of intrathecal pemetrexed is 15 mg, escalated to 20 mg, and then 25 mg....
Study NCT05289908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed (2)
Description: The maximum-tolerated dose determined in phase I study is chosen as the treatment dose in phase II study.
Study NCT05289908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: Folic acid 200-400 μg is administered orally once daily, prior to the first intrathecal pemetrexed, until 21 days after the last intrathecal pemetrexed.
Study NCT05289908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: A single dose of vitamin B12 1000 μg is administered by intramuscular injection before the first intrathecal pemetrexed, once per 3 weeks.
Study NCT05289908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone, 5 mg, intrathecal injection via lumbar puncture, simultaneously with pemetrexed, twice per week for 2 weeks, followed by once per week for 2-4 weeks.
Study NCT04725071 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Impact Advanced Recovery
Description: L-arginine and omega-3 rich supplement
Study NCT04725071 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Boost High Protein
Description: conventional supplement
Study NCT05795764 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Crisis Response Planning
Description: Crisis Response Planning (CRP) is a brief psychotherapeutic intervention.
Study NCT05795764 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Standard care provided for patients at risk for suicide
Study NCT06440538 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PCMS + Contralateral Motor Training
Description: PCMS + Contralateral Motor Training will involve delivering 360 pairs of TMS-PNS pulses (30min, 0.2 Hz) to the weaker first dorsal interosseous (FDI) muscle immediately before a session of ballistic index finger abduction training at the opposite, stronger FDI muscle.
Study NCT06440538 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PCMS + Rest
Description: PCMS + Rest will involve delivering 360 pairs of TMS-PNS pulses (30min, 0.2Hz) to the weaker FDI followed by a 30-min rest.
Study NCT06440538 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham PCMS + Contralateral Motor Training
Description: 360 TMS pulses will be delivered at a location 10-cm posterior to the participant's head (into the air, 0.2Hz) and no PNS pulses will be generated, followed by a session of 30-min ballistic index finger abduction training at the opposite, stronger FDI muscle.
Study NCT06274905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMLA
Description: EMLA cream
Study NCT06274905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethyl chloride
Description: Ethyl chloride
Study NCT06274905 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aqueous cream BP
Description: Aqueous cream
Study NCT05266274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD47 monoclonal antibody
Description: patients who meet the criteria are selected, CD47 monoclonal antibody combined with azacitidine is used for the treatment of patients with recurrent AML after transplantation